Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions

Drug Metabolism and Disposition

Volumn 35, Issue 2, 2007, Pages 246-255

  Obach, R Scott ^a   Walsky, Robert L ^a   Venkatakrishnan, Karthik ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPRAZOLAM; AMFEBUTAMONE; AMODIAQUINE; BUSPIRONE; CAFFEINE; CYTOCHROME P450; DEETHYLAMIODARONE; DESIPRAMINE; DEXTROMETHORPHAN; DICLOFENAC; DILTIAZEM; ERYTHROMYCIN; FURAFYLLINE; MEPHENYTOIN; MIDAZOLAM; MONTELUKAST; OMEPRAZOLE; PAROXETINE; PHENACETIN; RITONAVIR; TESTOSTERONE; THEOPHYLLINE; THIOTEPA; TICLOPIDINE; TIENILIC ACID; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; ZILEUTON;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; KINETICS; MICROSOMES, LIVER;

EID: 33846449874     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012633     Document Type: Article

References (53)

1. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, and Chung M (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:284-291.
2. Backman JT, Olkkola KT, Aranko K, Himberg JJ, and Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225.
3. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine : Comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.
4. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
5. Calvo G, Garcia-Gea C, Luque A, Morte A, Dal-Re R, and Barbanoj M (2004) Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. J Clin Psychopharmacol 24:268-276.
6. Chun J, Kent UM, Moss RM, Sayre LM, and Hollenberg PF (2000) Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane. Drug Metab Dispos 28:905-911.
7. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, and Scaltrini G (1987) Ticlopidinetheophylline interaction. Clin Pharmacol Ther 41:358-362.
8. Ernest CS, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
9. Faber MS and Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76:178-184.
10. Fromm MF, Busse D, Kroemer HK, and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
11. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175.
12. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
13. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, and Awni WM (1995) Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 29 (Suppl 2):77-83.
14. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, and Zinny MA (2003) Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 74:121-129.
15. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136.
16. Ha HR, Chen J, Krahenbuhl S, Follath F (1996) Biotransformation of caffeine by cDNAexpressed human cytochromes P-450. Eur J Clin Pharmacol 49:309-315.
17. Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
18. Heydari A, Rowland-Yeo K, Lennard MS, Ellis SW, Tucker GT, and Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32:1213-1217.
19. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
20. Ito K, Ogihara K, Kanamitsu SI, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954.
21. Kanamitsu SI, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000a) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res (NY) 17:419-426.
22. Kanamitsu SI, Ito K, and Sugiyama Y (2000b) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res (NY) 17:336-343.
23. Kivisto KT, Lamberg TS, Kantola T, and Neuvonen PJ (1997) Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 62:348-354.
24. Lamberg TS, Kivisto KT, and Neuvonen PJ (1998) of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 63:640-645.
25. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res (NY) 23:1089-1116.
26. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, and Goldman J (2002) Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 22:169-173.
27. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, and Rodrigues AD (2003) Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 31:1352-1360.
28. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
29. McConn DJ, Lin YS, Allen K, Kunze KL, and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083-1091.
30. Melet A, Assrir N, Jean P, Pilar Lopez-Garcia M, Marques-Soares C, Jaouen M, Dansette PM, Sari MA, and Mansuy D (2003) Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409:80-91.
31. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston BJ, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
32. Obach RS, Walsky RL, Venkatakrishnan K, Houston BJ, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
33. O'Reilly RA (1982) Ticrynafen-racemic warfarin interaction: hepatotoxic or stereoselective? Clin Pharmacol Ther 32:356-361.
34. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, and Maurel P (1992) Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41:1047-1055.
35. Polasek TM, Elliot DJ, Lewis BC, and Miners JO (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996-1007.
36. Racha JK, Rettie AE, and Kunze KL (1998) Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 37:7407-7419.
37. Richter T, Muerdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
38. Richter T, Schwab M, Eichelbaum M, and Zanger UM (2005) Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 69:517-524.
39. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748.
40. Rodopoulos N, Wisen O, and Norman A (1995) Caffeine metabolism in patients with chronic liver disease. Scand J Clin Lab Investig 55:229-242.
41. Rostami-Hodjegan A and Tucker GT (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Tech 1:441-448.
42. Silva JM and Nicholl-Griffith DA (2002) In vitro models for studying induction of cytochrome P450 enzymes, in Drug-Drug Interactions (Rodrigues AD ed) pp 189-216, Marcel Dekker, Inc., New York.
43. Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K, Urae A, Higuchi S, and Sawada Y (2000) Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 49:49-58.
44. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E, and Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9-18.
45. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, and Kobayashi S (1999) Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 47:454-457.
46. Thummel KE, Kunze KL, and Shen DD (2000) Metabolically based drug-drug interactions: principles and mechanisms, in Metabolic Drug Interactions (Levy RH et al. ed) pp 3-19, Lippincott Williams & Wilkins, Philadelphia.
47. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, and Laine K (2005) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553-559.
48. Venkatakrishnan K and Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33:845-852.
49. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
50. Walsky RL, Obach RS, Gaman EA, Gleeson JPR, and Proctor WR (2005) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418.
51. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
52. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 29:443-452.
53. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2005) Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 26:334-340.